Xarelto
Petition launched to raise AF and stroke awareness
April 20, 2012Business Services, Medical Communications, Sales and Marketing AF, Boehringer Ingelheim, Pradaxa, Xarelto, stroke
Various health organisations have called on more people involved in the management of atrial fibrillation (AF) to help raise awareness …
NICE wants more information on Xarelto
March 13, 2012Sales and Marketing Bayer, DVT, NICE, Xarelto
NICE is asking Bayer for more information about its blood thinner Xarelto in new guidance. The watchdog is currently minded …
NICE set to reject Xarelto in AF
January 10, 2012Sales and Marketing AF, NICE, Pradaxa, Xarelto, atrial fibrillation
NICE says it needs more data on Bayer’s Xarelto in order to recommend it for people with atrial fibrillation. The …
Xarelto succeeds in new study
November 14, 2011Sales and Marketing Bayer, FDA, J&J, JJ, Xarelto
In a new study J&J and Bayer’s blood thinner Xarelto reduced deaths in patients after a heart attack, which could …
Emerging markets help Bayer through tough quarter
October 28, 2011Sales and Marketing Bayer, Xarelto, emerging markets
Bayer has posted modest results for the third quarter, with growth in emerging markets compensating for austerity measures in Europe …
Astellas abandons oral anticoagulant darexaban
September 30, 2011Research and Development Astellas, Eliquis, Xarelto, darexaban
Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …
Xarelto poised for two new chronic indications
September 26, 2011Sales and Marketing Xarelto
Bayer HealthCare’s oral bloodthinner Xarelto has been recommended for approval in Europe for two new chronic indications. The Committee for …
Eliquis launched in the UK
September 19, 2011Sales and Marketing Eliquis, Pradaxa, VTE, Xarelto
Eliquis, the latest entrant to the competitive oral anticoagulant market, has been launched in the UK.Co-developed and co-marketed by Pfizer …
FDA recommends Xarelto for new approval
September 12, 2011Sales and Marketing Xarelto, atrial fibrillation, stroke
FDA advisors have recommended Bayer and Johnson & Johnson’s Xarelto be approved in the US for the prevention of stroke …
Pradaxa and Eliquis gain trial boost over warfarin
August 31, 2011Sales and Marketing Eliquis, Pradaxa, Xarelto, apixaban
A pair of new blood thinners are superior to warfarin when it comes to reducing the risk of stroke in …
Xarelto receives FDA approval
July 4, 2011Sales and Marketing Bayer, Eliquis, Johnson & Johnson, Pradaxa, Xarelto, anticoagulant
Bayer and Johnson & Johnson’s oral blood thinner Xarelto has been approved in the US for the prevention of deep …
NICE to appraise hep C drugs Victrelis and telaprevir
May 26, 2011Sales and Marketing Brinavess, Ilaris, NICE, Victrelis, Xarelto, Zytiga, telaprevir
NICE’s next round of drug appraisals is set to include two new hepatitis C drugs – Merck Sharpe and Dohme’s …
Merck drops oral anticoagulant
March 25, 2011Merck, Pradaxa, Xarelto, anticoagulant, atrial fibrilation, vorapaxar
Merck has given the rights to its oral anticoagulant betrixaban back to Portola Pharmaceuticals after a review of its late …
Bayer goes for pharma growth
March 1, 2011Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto
While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …
Key drug launches for 2011
January 20, 2011Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir
This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …
Latest content
FibroFind appoints Lee Borthwick as CEO
